Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Trial Profile

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Trigriluzole (Primary)
  • Indications Spinocerebellar ataxias
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 11 Feb 2019 Planned initiation date changed from 31 Jan 2019 to 15 Mar 2019.
    • 17 Dec 2018 Planned initiation date changed from 15 Nov 2018 to 31 Jan 2019.
    • 08 Oct 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top